Other OTC - Delayed Quote USD

Gene Biotherapeutics, Inc. (CRXM)

0.0000 0.0000 (0.00%)
As of February 9 at 2:22 PM EST. Market Open.

Key Executives

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Christopher J. Reinhard Co-Founder, CEO, President, Treasurer & Director 240k -- 1954
Mr. James L. Grainer Chairman, CFO & Secretary -- -- 1955
Dr. Lois A. Chandler Chief Operating Officer -- -- 1958
Dr. Ronald J. Shebuski Chief Scientific Officer -- -- 1953
Mr. Duane Linstrom General Counsel 119.23k -- --

Gene Biotherapeutics, Inc.

11230 Sorrento Valley Road
Suite 220
San Diego, CA 92121
United States
858 414 1477 https://genebiotherapeutics.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
3

Description

Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.

Corporate Governance

Gene Biotherapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Related Tickers

NAVB Navidea Biopharmaceuticals, Inc.
0.0440
+17.33%
 
AEZS Aeterna Zentaris Inc.
1.9501
-1.51%
 
LCTX Lineage Cell Therapeutics, Inc.
1.1350
+3.20%
 
FGEN FibroGen, Inc.
0.9786
-0.58%
 
AKBA Akebia Therapeutics, Inc.
1.3212
-3.56%